Identification of prognostic biomarkers for antibiotic associated nephrotoxicity in cystic fibrosis
Life expectancy in cystic fibrosis (CF) is near 50 years, thanks to novel therapies and improved diagnostics [1]. This remarkable progress is attenuated by an increasing prevalence of comorbidities. In CF, the prevalence of chronic kidney disease (CKD) is 2.3 %, double that of the general population when adjusted for age, and prevalence doubles with every 10-year increase in age [2]. One major risk factor for CKD is repeated administration of nephrotoxic antibiotics, such as aminoglycosides and polymyxin E (colistin), to treat pulmonary exacerbations.
Source: Journal of Cystic Fibrosis - Category: Respiratory Medicine Authors: Andrew Hart, Francine Cesar, Leila R Zelnick, Nick O'Connor, Zoie Bailey, Jordan Lo, Kirk Van Ness, Ian B. Stanaway, Theo K. Bammler, James W. MacDonald, Matthew R. Thau, Jonathan Himmelfarb, Christopher H. Goss, Moira Aitken, Edward J. Kelly, Pavan K. Bh Tags: Original Article Source Type: research